远大医药GPN01020获国家药监局批准开展偏头痛预防II期临床试验

美股速递
Mar 25

远大医药集团有限公司宣布,其研发的GPN01020已获得中国国家药品监督管理局(NMPA)批准,将正式进入针对偏头痛预防的II期临床试验阶段。

这一重要进展标志着公司在该创新药物研发道路上迈出了关键一步,有望为偏头痛患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10